Supriya lifescience Limited has filed its quarterly compliance certificate with stock exchanges, confirming adherence to SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE Limited and National Stock Exchange of India Limited on April 10, 2026.

Regulatory Compliance Certificate

The certificate was issued by MUFG Intime India Private Limited, formerly Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent. The document, dated April 3, 2026, confirms compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Certificate Confirmation Details

MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories. The registrar verified that all securities comprised in the certificates have been listed on stock exchanges where the company's previously issued securities are traded.

The certificate also confirms that security certificates received for dematerialisation were appropriately confirmed or rejected, and the physical certificates were mutilated and cancelled after due verification by the depository participant. The names of the depositories have been substituted in the register of members as registered owners within prescribed timelines.

Company Secretary Filing

Prachi Sathe, Company Secretary and Compliance Officer of Supriya Lifescience Limited, digitally signed and submitted the compliance certificate to the stock exchanges. The filing was completed on April 10, 2026, ensuring timely regulatory compliance.

Corporate Information

Supriya Lifescience Limited operates from its corporate office in Mumbai and maintains manufacturing facilities in Maharashtra. The company is recognized as a Government Recognised Export House and continues to maintain its regulatory compliance obligations across all operational quarters.

Supriya lifescience Limited has announced the completion of tenure for two independent directors as part of its regulatory disclosure obligations. The pharmaceutical company informed stock exchanges about this significant board development on March 24, 2026.

Directors' Tenure Completion

The company disclosed that the five-year consecutive terms of Mr. Dinesh Navnitlal Modi (DIN: 00004556) and Mr. Dileep Kumar Jain (DIN: 00380311) as independent directors concluded on March 24, 2026. Both directors completed their statutory maximum tenure as independent directors under corporate governance norms.

The board members conveyed their sincere appreciation for the contributions made by these directors during their long-term association with the company.

Board Committee Reconstitution

Following the directors' tenure completion, the board reconstituted its key committees during its meeting held on February 09, 2026. The restructured committees ensure continued compliance with corporate governance requirements.

Audit Committee:

Nomination and Remuneration Committee:

Stakeholders' Relationship Committee:

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company secretary and compliance officer, Prachi Sathe, signed the disclosure document ensuring proper regulatory compliance.

This board transition represents a routine corporate governance process as independent directors complete their maximum permissible tenure, ensuring fresh perspectives and continued adherence to independence requirements in board composition.